Strides Pharma Gains 2.86%: Mixed Technical Signals Shape Weekly Momentum

15 September: Technical Momentum Signals Bullish Outlook Despite Price Dip

Strides Pharma began the week with a 2.83% decline to close at ₹1,152.50, underperforming the Sensex which fell 1.69% to 35,169.62. This dip followed a technical momentum shift signalling an improved bullish trend, supported by daily moving averages and bullish monthly MACD readings. Despite the price pullback, the stock maintained strength above key moving averages, indicating underlying resilience.

Volume stood at 26,418 shares, reflecting moderate trading interest. The stock’s 52-week high remained at ₹1,231.45, with a low of ₹769.60, underscoring a strong recovery trajectory over the past year. The MarketsMOJO grade had recently been upgraded to Buy on 8 September, reflecting growing investor confidence amid strong relative returns versus the Sensex.

16 September: Downgrade to Hold Amid Mixed Technical and Financial Signals

The stock closed unchanged at ₹1,152.50 on 16 September, marking a 2.83% drop from the previous close, while the Sensex gained 0.30%. This day was marked by a downgrade in the MarketsMOJO mojo grade from Buy to Hold, reflecting a more cautious stance due to mixed technical and financial indicators.

Technical indicators softened from bullish to mildly bullish, with weekly and monthly MACD remaining positive but KST and Dow Theory oscillators turning mildly bearish. Financially, the company showed strong operating profit growth of 27.28% annually and a peak operating cash flow of ₹702.52 crores, but concerns over debt servicing and increased promoter share pledging (38.1% pledged) tempered enthusiasm.

The stock’s valuation remained attractive, with a low PEG ratio of 0.3 and a ROCE of 15.5%, but the downgrade reflected the need for caution amid these mixed signals.

17 September: Bullish Momentum Returns with Technical Upgrades

On 17 September, Strides Pharma rebounded strongly, gaining 3.13% to close at ₹1,188.55, outperforming the Sensex’s 0.46% gain. The stock traded within a range of ₹1,102.35 to ₹1,192.00, nearing its 52-week high of ₹1,231.45. This price surge was supported by a technical trend upgrade from mildly bullish to bullish, with MACD indicators on weekly and monthly charts signalling strengthening momentum.

Daily moving averages remained bullish, and Bollinger Bands indicated strong buying pressure. However, the Know Sure Thing oscillator remained mildly bearish, suggesting some caution. Volume was moderate at 14,508 shares, with On-Balance Volume bullish on monthly charts but neutral weekly, indicating longer-term accumulation despite short-term uncertainty.

Relative to the Sensex, Strides Pharma’s one-month return stood at 22.78%, significantly outperforming the benchmark’s 4.71% decline. Year-to-date, the stock delivered a 31.72% gain versus the Sensex’s negative 12.77%, underscoring its strong sector positioning.

18 September: Mixed Indicator Signals Amid Technical Momentum Shift

The week closed on a cautiously optimistic note as Strides Pharma gained 0.97% to ₹1,200.05 on 18 September, while the Sensex rose 0.52%. The stock traded between ₹1,161.20 and ₹1,213.30, consolidating near its 52-week high. Technical momentum shifted from bullish to mildly bullish, reflecting a blend of positive and cautionary signals.

MACD remained bullish on weekly and monthly charts, supporting sustained upward momentum. However, the monthly RSI turned bearish, and the Know Sure Thing oscillator was mildly bearish on both timeframes, indicating potential moderation in momentum. Bollinger Bands stayed bullish, with the stock trading near the upper band, signalling strong buying interest but also risk of short-term pullbacks.

Daily moving averages continued to provide support, while On-Balance Volume was bullish monthly but neutral weekly. The MarketsMOJO mojo score remained at 64.0 with a Hold rating, reflecting tempered analyst optimism amid mixed technical signals.

Key Takeaways

Strides Pharma Science Ltd demonstrated a resilient performance this week, gaining 2.86% against a 0.41% decline in the Sensex. The stock’s ability to rebound after an early-week dip and sustain gains near its 52-week high highlights underlying strength supported by bullish MACD and moving averages.

However, the downgrade from Buy to Hold by MarketsMOJO reflects a more cautious stance due to mixed technical signals, including mildly bearish KST and Dow Theory indicators, and a bearish monthly RSI. Financially, while operating profit growth and cash flow remain strong, concerns over debt servicing and increased promoter share pledging introduce risk factors.

The stock’s valuation metrics remain attractive, with a low PEG ratio and healthy ROCE, supporting its long-term growth narrative. Volume trends suggest longer-term accumulation despite short-term fluctuations, indicating sustained investor interest.

Overall, the week’s events underscore a stock in transition: exhibiting bullish momentum tempered by cautionary signals. Investors should monitor key technical levels and volume patterns closely to assess the sustainability of the current uptrend.

Conclusion

Strides Pharma Science Ltd’s 2.86% weekly gain amid a declining Sensex reflects its strong relative performance and sector resilience. The week was marked by a technical momentum shift from bullish to mildly bullish, a downgrade in mojo grade, and mixed signals from key indicators. While the stock’s fundamentals and valuation remain compelling, emerging risks related to debt and promoter pledging warrant a balanced approach.

As the stock consolidates near its 52-week high, the interplay of bullish MACD and moving averages with cautionary RSI and KST readings suggests that momentum may moderate in the near term. Investors should remain vigilant, weighing the stock’s impressive long-term returns against the evolving technical landscape and market conditions.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →